These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11738743)

  • 1. Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine.
    Chujoh Y; Matsuo K; Yoshizaki H; Nakasatomi T; Someya K; Okamoto Y; Naganawa S; Haga S; Yoshikura H; Yamazaki A; Yamazaki S; Honda M
    Vaccine; 2001 Dec; 20(5-6):797-804. PubMed ID: 11738743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.
    Honda M; Matsuo K; Nakasone T; Okamoto Y; Yoshizaki H; Kitamura K; Sugiura W; Watanabe K; Fukushima Y; Haga S; Katsura Y; Tasaka H; Komuro K; Yamada T; Asano T; Yamazaki A; Yamazaki S
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10693-7. PubMed ID: 7479867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
    Zolla-Pazner S; Cohen S; Pinter A; Krachmarov C; Wrin T; Wang S; Lu S
    Virology; 2009 Sep; 392(1):82-93. PubMed ID: 19632700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop.
    Kameoka M; Nishino Y; Matsuo K; Ohara N; Kimura T; Yamazaki A; Yamada T; Ikuta K
    Vaccine; 1994 Feb; 12(2):153-8. PubMed ID: 8147098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
    Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
    J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen.
    Kawahara M; Matsuo K; Nakasone T; Hiroi T; Kiyono H; Matsumoto S; Yamada T; Yamamoto N; Honda M
    Vaccine; 2002 Dec; 21(3-4):158-66. PubMed ID: 12450689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.
    Smith AD; Geisler SC; Chen AA; Resnick DA; Roy BM; Lewi PJ; Arnold E; Arnold GF
    J Virol; 1998 Jan; 72(1):651-9. PubMed ID: 9420270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
    Davis KL; Gray ES; Moore PL; Decker JM; Salomon A; Montefiori DC; Graham BS; Keefer MC; Pinter A; Morris L; Hahn BH; Shaw GM
    Virology; 2009 May; 387(2):414-26. PubMed ID: 19298995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
    Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
    J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions.
    Hiroi T; Goto H; Someya K; Yanagita M; Honda M; Yamanaka N; Kiyono H
    J Immunol; 2001 Nov; 167(10):5862-7. PubMed ID: 11698461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency of recombinant bacille Calmette-Guérin in inducing humoral and cell mediated immunities against human immunodeficiency virus type 1 third variable domain in immunized mice.
    Kim YJ
    Yonsei Med J; 2011 Jan; 52(1):173-80. PubMed ID: 21155051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
    Berman PW; Gray AM; Wrin T; Vennari JC; Eastman DJ; Nakamura GR; Francis DP; Gorse G; Schwartz DH
    J Infect Dis; 1997 Aug; 176(2):384-97. PubMed ID: 9237703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope.
    Wu L; Yang ZY; Xu L; Welcher B; Winfrey S; Shao Y; Mascola JR; Nabel GJ
    Vaccine; 2006 Jun; 24(23):4995-5002. PubMed ID: 16690178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
    Gorny MK; Mascola JR; Israel ZR; VanCott TC; Williams C; Balfe P; Hioe C; Brodine S; Burda S; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):213-21. PubMed ID: 9491911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.